Translating science Transforming lives
Innovation, fueled by science and a passion for patients
PTC is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults living with serious diseases of high unmet need. Our ability to identify innovative new therapies and globally commercialize products is the foundation that drives investment in a diversified pipeline.
Our Scientific Platforms
Groundbreaking Science
Our approved therapies in the U.S. and other countries include a series of firsts: the first approved treatment for Duchenne muscular dystrophy in the world, the first approved gene therapy directly infused into the brain, and the first approved small molecule splicing modifier. We continue to invest in a diverse pipeline for conditions with significant unmet need.
Clinical Trials
We are committed to making progress in rare disease through clinical trial research.
Working as OnePTC
As One PTC, we feel the urgent call to help those with significant unmet needs. We are motivated to provide treatments and new possibilities for our patients.
Doing things that no one’s ever done before is hard. That doesn’t deter us.
If you’re looking to take on rewarding work with inspiring colleagues, come grow with us.
Making headlines
-
PRESS RELEASE
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
PTC Therapeutics will host a webcast conference call on April 28 to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. -
PRESS RELEASE
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
PTC Therapeutics announced that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET. -
PRESS RELEASE
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
PTC announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise.
PTC works closely with healthcare providers to support their needs
Support for the PTC patient, family, and caregiver community
Explore our investor relations section and sign up for alerts on important PTC developments